Termination fees have come more into focus, given the increase in spoiler bids, particularly high-profile ones such as Boston Scientific Corp.’s $27 billion intrusion on Johnson & Johnson’s definitive for Guidant Corp.
To read the entire story, you must be logged in.
Please log in now or register with us.
